Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.

[1]  B. Thjódleifsson,et al.  A randomized, double‐blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro‐oesophageal reflux disease over 5 years , 2003, Alimentary pharmacology & therapeutics.

[2]  K. Goh.  Update on the management of Helicobacter pylori infection, including drug‐resistant organisms , 2002, Journal of gastroenterology and hepatology.

[3]  C. O'Morain,et al.  Treatment of Helicobacter pylori infection and factors influencing eradication , 2002, Alimentary pharmacology & therapeutics.

[4]  E. Solcia,et al.  Effects of Very Long (up to 10 Years) Proton Pump Blockade on Human Gastric Mucosa , 2009, Digestion.

[5]  K. Geboes,et al.  Long‐term lansoprazole treatment for gastro‐oesophageal reflux disease: clinical efficacy and influence on gastric mucosa , 2001, Alimentary pharmacology & therapeutics.

[6]  A. Axon,et al.  Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. , 2001, Gastroenterology.

[7]  F. Mégraud.  Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  E. Kuipers,et al.  Antibiotic resistance of Helicobacter pylori , 2001, Symposium series.

[9]  J. Polak,et al.  Pantoprazole therapy in the long-term management of severe acid peptic disease Clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies , 2001, American Journal of Gastroenterology.

[10]  E. Kuipers,et al.  Helicobacter pylori eradication for the prevention of atrophic gastritis during omeprazole therapy; A prospective randomized trial , 2001 .

[11]  R. Lahaie,et al.  Helicobacter pylori antibiotic resistance: trends over time. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[12]  R. Hunt,et al.  Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[13]  C. Fallone.  Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[14]  D. Graham,et al.  Antibiotic-resistant H. pylori infection and its treatment. , 2000, Current pharmaceutical design.

[15]  Walsh,et al.  Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[16]  J. Dent,et al.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. , 2000, Gastroenterology.

[17]  D. Peura.  The problem of Helicobacter pylori-negative idiopathic ulcer disease. , 2000, Bailliere's best practice & research. Clinical gastroenterology.

[18]  Thijs,et al.  Review article: nitroimidazole resistance in Helicobacter pylori , 2000, Alimentary pharmacology & therapeutics.

[19]  J. Kleibeuker,et al.  Nitroimidazole resistance in Helicobacter pylori , 2000 .

[20]  M. Stolte,et al.  Lack of effect of acid suppression therapy on gastric atrophy. , 2000, Gastroenterology.

[21]  L. Lundell,et al.  Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. , 1999, Gastroenterology.

[22]  E. Kuipers,et al.  Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. , 1999 .

[23]  Lamers,et al.  Hypergastrinaemia during long‐term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection , 1998, Alimentary pharmacology & therapeutics.

[24]  K. Bardhan,et al.  A six-year assessment of tinidazole, metronidazole, clarithromycin, tetracycline and amoxicillin resistance in Helicobacter pylori clinical isolates: A rising tide of antibiotic resistance? , 1998 .

[25]  A. Berstad,et al.  Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole , 1997, Alimentary pharmacology & therapeutics.

[26]  B. Simon,et al.  Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. , 1997, Gastroenterology.

[27]  E. Kuipers,et al.  Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. , 1996, The New England journal of medicine.

[28]  A. Blum,et al.  Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. , 1996, Gastroenterology.

[29]  A. Blum,et al.  Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. , 1995, Gut.

[30]  J. Jansen,et al.  Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety , 1994, Annals of Internal Medicine.

[31]  G. Brunner,et al.  Long‐term therapy with pantoprazole in patients with peptic ulceration resistant to extended high‐dose ranitidine treatment. , 1994, Alimentary pharmacology & therapeutics.

[32]  R. Arnold,et al.  An open trial of long‐term therapy with lansoprazole in patients with peptic ulceration resistant to extended high‐dose ranitidine treatment , 1993, Alimentary pharmacology & therapeutics.

[33]  R. Fiocca,et al.  Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. , 1992, Digestion.

[34]  P. Sipponen,et al.  The Sydney System: Epidemiology and natural history of chronic gastritis , 1991, Journal of Gastroenterology and Hepatology.